KRAS and cancer: To test its potency against KRAS and BRAF mutant colorectal cancer cells, we treated three KRAS-mutant cancer cell lines (HCT116, LS513, and SW620) or a BRAF-mutant cancer cell line (HT29) with SJ-C1044 in a cell growth assay.